paroxetine qt

paroxetine qt

FILE PHOTO: A medical worker prepares a dose of AstraZeneca COVID-19 vaccine at a vaccination center, amid the coronavirus disease outbreak, in Ronquieres, Belgium April 6, 2021. REUTERS/Yves Herman/File Photo

LONDON (Reuters) – AstraZeneca on Wednesday said it was working with European and British regulators to change the product information on its COVID-19 shot after authorities said they suspected possible brain blood clots were a rare side-effect of the shot.

“Both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” AstraZeneca said in a statement.

“However, they came to the view that these events have a possible link to the vaccine and requested they be listed as an extremely rare potential side effect … AstraZeneca has been actively collaborating with the regulators to implement these changes to the product information.”

Source: Read Full Article